Sean Grant Sells 4,949 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sean Grant sold 4,949 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $207,759.02. Following the completion of the transaction, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at $4,793,318.38. The trade was a 4.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Vera Therapeutics Price Performance

Shares of NASDAQ:VERA traded down $0.69 during trading on Wednesday, reaching $41.68. 776,869 shares of the company’s stock traded hands, compared to its average volume of 897,432. The company has a quick ratio of 12.21, a current ratio of 12.21 and a debt-to-equity ratio of 0.19. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $56.05. The company has a 50-day simple moving average of $46.63 and a 200-day simple moving average of $35.30. The firm has a market cap of $2.92 billion, a PE ratio of -10.45 and a beta of 1.16.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VERA. Pivotal Research set a $73.00 target price on Vera Therapeutics in a research report on Friday, December 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a report on Wednesday, January 21st. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. The Goldman Sachs Group upped their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price objective on shares of Vera Therapeutics in a report on Friday, November 28th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $77.18.

Hedge Funds Weigh In On Vera Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC raised its holdings in Vera Therapeutics by 50.5% in the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after acquiring an additional 236 shares during the last quarter. Optimize Financial Inc grew its position in shares of Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after purchasing an additional 256 shares in the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock valued at $271,000 after purchasing an additional 290 shares during the last quarter. Intech Investment Management LLC lifted its position in Vera Therapeutics by 2.4% during the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock worth $903,000 after buying an additional 424 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Vera Therapeutics by 2.0% during the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after buying an additional 550 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.